These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31189966)

  • 1. Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study.
    Lee JY; Jang SY; Nam CM; Kang ES
    Sci Rep; 2019 Jun; 9(1):8532. PubMed ID: 31189966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
    Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES
    Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.
    Arvind A; Memel ZN; Philpotts LL; Zheng H; Corey KE; Simon TG
    Metabolism; 2021 Jul; 120():154780. PubMed ID: 33891949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
    Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
    Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
    Douros A; Yin H; Yu OHY; Filion KB; Azoulay L; Suissa S
    Diabetes Care; 2017 Nov; 40(11):1506-1513. PubMed ID: 28864502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study.
    Kim G; Jang SY; Nam CM; Kang ES
    J Hepatol; 2018 Mar; 68(3):476-484. PubMed ID: 29107150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of hepatocellular carcinoma risk between patients treated with glimepiride and gliclazide.
    Lee JY; Kim G; Lee YH; Lee BW; Cha BS; Nam CM; Kang ES
    Diabetes Metab; 2019 Jan; 45(1):83-85. PubMed ID: 28778564
    [No Abstract]   [Full Text] [Related]  

  • 8. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
    Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus.
    Cho EH; Han K; Kim B; Lee DH
    Medicine (Baltimore); 2020 Jul; 99(29):e21236. PubMed ID: 32702900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-diabetic medications and the risk for colorectal cancer: A population-based nested case-control study.
    Shin CM; Kim N; Han K; Kim B; Jung JH; Oh TJ; Lee DH
    Cancer Epidemiol; 2020 Feb; 64():101658. PubMed ID: 31887708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection.
    Kawaguchi T; Taniguchi E; Morita Y; Shirachi M; Tateishi I; Nagata E; Sata M
    Liver Int; 2010 Mar; 30(3):479-86. PubMed ID: 20040053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus.
    Hassan MH; Abd-Allah GM
    Pak J Pharm Sci; 2015 Sep; 28(5):1723-30. PubMed ID: 26408873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.
    Donadon V; Balbi M; Casarin P; Vario A; Alberti A
    World J Gastroenterol; 2008 Oct; 14(37):5695-700. PubMed ID: 18837086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
    Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
    Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
    Abdelmoneim AS; Eurich DT; Senthilselvan A; Qiu W; Simpson SH
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1186-1195. PubMed ID: 27102581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of severe hypoglycemic events from amiodarone-sulfonylureas interactions: A population-based nested case-control study.
    Lai JH; Wang MT; Wu CC; Huang YL; Lu CH; Liou JT
    Pharmacoepidemiol Drug Saf; 2020 Aug; 29(8):842-853. PubMed ID: 32483856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of fasting serum glucose level and type 2 diabetes with hepatocellular carcinoma in men with chronic hepatitis B infection: A large cohort study.
    Kim K; Choi S; Park SM
    Eur J Cancer; 2018 Oct; 102():103-113. PubMed ID: 30189372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea.
    Yi SW; Choi JS; Yi JJ; Lee YH; Han KJ
    Cancer; 2018 Jul; 124(13):2748-2757. PubMed ID: 29669170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is gliclazide a sulfonylurea with difference? A review in 2016.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.